Prevalence of Osteoporosis in Sickle Cell Disease (DREPAN'OS)
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
Sickle cell disease is the most common single-gene disease in the world. Its prevalence is increasing in France, with patients' life expectancy increasing into developed countries. It mainly affects populations originating from sub-Saharan Africa. Among the chronic bone complications associated with sickle cell disease, osteoporosis has previously been highlighted but remains a poorly known complication in this very particular context. A dedicated evaluation of osteoporosis and associated risk factors in sickle cell disease patients living in France may enable better bone management of these patients in the future, as this problem, specific to their disease, is likely to become more frequent as their life expectancy increases.
This is a prospective interventional and monocentric study whose objective is to describe the prevalence of osteoporosis in black patients with sickle cell disease in France
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Black-skinned men and women
- Aged 20 to 40 years old
- Sickle cell patients
- Non-opposition to participate in the study
Exclusion criteria
- Refusal to participate in the study
- Hemoglobinopathy other than sickle cell disease
- Severe or End Stage Renal Failure
- Long-term corticosteroid therapy (>3 months)
- History of solid cancer or malignant haemopathy
- History of organ transplantation
- Pregnant or breastfeeding woman
- Psychiatric pathology seriously impeding understanding
- Difficulty understanding oral French
Trial design
142 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal